Clinical Trial Update: Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage [Phase 1]

View source ↗

Summary

A Phase 1 safety study of CN-105 for intracerebral hemorrhage has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage

Drugs mentioned

• CN-105 (CN-105)

Snippet

Sponsor: AegisCN LLC | Conditions: Intracerebral Hemorrhage (ICH) | Phase 1 | Status: COMPLETED